Access Industries contributed to a round that lifted the bone marrow transplant drug developer's overall funding to $150m.
Magenta Therapeutics, a US-based developer of drugs to aid bone marrow transplantation, closed a $52m series C round that included diversified conglomerate Access Industries today.
Investment firm Casdin Capital led the round, which also featured cellular technology services provider Be the Match BioTherapies, EcoR1 Capital, Eventide Asset Management and Watermill Asset Management.
Magenta is working on therapeutics that will enhance the curative powers of bone marrow transplants. It will use the series C proceeds to advance its product pipeline,…
